All News
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab
d
MedPage Today
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
Read Article
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.
Read Article
Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.
Read Article
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/VH2ahP1XUy
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3
Links:
Dr. John Cush RheumNow ( View Tweet)
Sedentary Behavior Increases the Risk of Gout
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia.
https://t.co/LDhK3iDnrS https://t.co/z6I6tRw9Fr
Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/IibXiitVY8 https://t.co/XHBQcdcMAE
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: Active Lupus on pred + DMARD w/ (more than skin/Joint) organ & serologic activity- whats your preferred "add-on" drug?
Dr. John Cush RheumNow ( View Tweet)
Italian study of 458 #RA pts shows 16% (71)meeting the EULAR criteria for difficult 2 Rx RA ( D2T-RA); unrelated to age, gender, seropositivity. BUT D2T-RA was assoc w/ erosions (24% vs 11%), obesity (33% vs 19%) & FM (25% vs 10%) https://t.co/w5mliNkfBT https://t.co/m65jk62wmh
Dr. John Cush RheumNow ( View Tweet)
Retrospectively review of 165 #EGPA pts, GI manifestations were assoc w/ Eosinophils > 19.5%, weight loss, & myalgia; & included abdominal pain (78%), diarrhea (40%), N/V (33%); GI hemorrhage (27%), ulcers (17%), obstruction (10%), & pancreatitis (6%) https://t.co/EzsGcFs2l2 https://t.co/mQrgjTG6NV
Dr. John Cush RheumNow ( View Tweet)
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/AEJmW95vud https://t.co/3NnKjHQJtv
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women
https://t.co/RxI1zlZ9YR https://t.co/vhsLi6HQAS
Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis
Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction?
#ACR24 @RheumNow Abstr#0670 https://t.co/ug2ZzzSrGi https://t.co/O6r1e8ioO0
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus
https://t.co/aNk5pgBpiJ https://t.co/C427ayULng
Dr. John Cush RheumNow ( View Tweet)
Best of 2024: Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency
https://t.co/Fkn26crcNX https://t.co/LJVa0TApid
Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD.
30% of ILD has cough
Chest CT 91% sensitive, 71% specific
5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality
Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/s5v3XD8QmC https://t.co/iP5yFWkQwb
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V
Links:
Dr. John Cush RheumNow ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow… https://t.co/lJ95hYO3vM https://t.co/zF9esDnLYh
Dr. John Cush RheumNow ( View Tweet)
post-hoc analysis 48 pts w/ SSc-ILD in the DESIRES trial (DBRPCT) showed that RTX efficacy on lung outcomes (FVC change) at 24 weeks was only seen in those with CRP levels ≥0.055 mg/dl, ΔppFVC was significantly higher w RTX vs PBO [difference 8%) https://t.co/92yfWEU1d8 https://t.co/tB9sd9VS1K
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 5063 SLE patients, found fibromyalgia (FM) 15.8% (high heterogeneity I2- 98%). SLE pts had a 3.7 fold higher risk of FM. FM in SLE was a confounder in assessing disease activity and treatment response. FM is a frequent comorbidity in SLE https://t.co/0fSIl480PG https://t.co/6ZtAovPVnD
Dr. John Cush RheumNow ( View Tweet)
Calcinosis cutis affects 20–40% of systemic sclerosis pts - and nothing works! PRELIMINARY animal and invitro studies suggest that Citric acid is more effective than sodium thiosulfate in chelating calcium in a dissolution model of calcinosis https://t.co/Cbzi00xHdb https://t.co/JLSIyOdxKb
Dr. John Cush RheumNow ( View Tweet)